BRAF and breast cancer: Systemic drug responses were monitored via <sup>99m</sup>Tc pertechnetate gamma counting and SPECT/CT imaging in wild-type BALB/c and Tg-rtTA/tetO-BRAF<sup>V600E</sup> mice, as well as orthotopic NOD.Cg-Prkdc<sup>scid</sup> Il2rg<sup>tm1Wjl</sup>/SzJ (NSG) breast cancer.<h4>Findings</h4>Copper diethyldithiocarbamate (Cu(DDC)<sub>2</sub>), a metabolite of the FDA-approved drug disulfiram, modulated NIS function in thyroid and breast cancer cells (P < 0.05).